The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN

Journal of Drug Targeting

Volumn 16, Issue 7-8, 2008, Pages 564-577

  Raney, Sameersingh ^a   Wilson, Kaley ^b   Sekirov, Laura ^a   Chikh, Ghania ^a   de Jong, Susan ^b   Cullis, Pieter ^b   Tam, Ying ^a  

^a Tekmira Pharmaceuticals Corporation   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adjuvant; Biodistribution; CpG oligodeoxynucleotide; Immunostimulatory; Liposomal nanoparticle; Pharmacokinetics

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; LIPID NANOPARTICLE; LIPOSOME; NANOPARTICLE; RITUXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CELL; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CIRCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LIPID COMPOSITION; MOUSE; NANOENCAPSULATION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; BASE SEQUENCE; CPG ISLANDS; FEMALE; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; LIPIDS; MICE; MICE, INBRED STRAINS; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 49149106239     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860802228756     Document Type: Article

References (29)

1. Allen, TM and Cullis, PR (2004) Drug delivery systems: Entering the mainstream. Science, 303:5665, pp. 1818-1822.
2. Allen, TM Hansen, C. et al. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta, 1066:1, pp. 29-36.
3. Alving, CR (1991) Liposomes as carriers of antigens and adjuvants. J Immunol Methods, 140:1, pp. 11-13.
4. Bligh, EG and Dyer, WJ (1959) rapid method of total lipid extraction and purification. Can J Biochem Physiol, 37:8, pp. 911-917.
5. Cabanes, A. Briggs, KE et al. (1998) Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel. Int J Oncol, 12:5, pp. 1035-1040.
6. Chen, WC and Huang, L. (2005) Non-viral vector as vaccine carrier. Adv Genet, 54, pp. 315-337.
7. de Jong, S. Chikh, G. et al. (2007) Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother
8. Gregoriadis, G. (1988) Liposomes as drug carriers: Recent trends and progress, John Wiley and Sons, Chichester, UK
9. Gregoriadis, G. (1994) The immunological adjuvant and vaccine carrier properties of liposomes. J Drug Target, 2:5, pp. 351-356.
10. Gregoriadis, G. (1995) Engineering liposomes for drug delivery: Progress and problems. Trends Biotechnol, 13:12, pp. 527-537.
11. Harris, JM and Chess, RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov, 2:3, pp. 214-221.
12. Hashizume, H. Baluk, P. et al. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol, 156:4, pp. 1363-1380.
13. Hemmi, H. Takeuchi, O. et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature, 408:6813, pp. 740-745.
14. Jain, RK (1987) Transport of molecules across tumor vasculature. Cancer Metastasis Rev, 6:4, pp. 559-593.
15. Johnston, MJ Semple, SC et al. (2006) Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta, 1758:1, pp. 55-64.
16. Juliano, RL (1986) Liposomes and the reticuloendothelial system: interactions of liposomes with macrophages and behavior of liposomes in vivo. Life Sci, 113, pp. 285-300.
17. Klimuk, SK Semple, SC et al. (2000) Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. J Pharmacol Exp Ther, 292:2, pp. 480-488.
18. Kobayashi, KS and Flavell, RA (2004) Shielding the double-edged sword: Negative regulation of the innate immune system. J Leukoc Biol, 75:3, pp. 428-433.
19. Lang, T. and Mansell, A. (2007) The negative regulation of Toll-like receptor and associated pathways. Immunol Cell Biol, 85:6, pp. 425-434.
20. Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41, pp. 189-207.
21. Maeda, H. Wu, J. et al. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release, 65:1, pp. 271-284.
22. Maurer, N. Wong, KF et al. (2001) Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J, 80:5, pp. 2310-2326.
23. Meerum Terwogt, JM Groenewegen, G. et al. (2002) Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol, 49:3, pp. 201-210.
24. Mui, B. Raney, SG et al. (2001) Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther, 298:3, pp. 1185-1192.
25. Oja, CD Semple, SC et al. (1996) Influence of dose on liposome clearance: Critical role of blood proteins. Biochim Biophys Acta, 1281:1, pp. 31-37.
26. Semple, SC Klimuk, SK et al. (2000) Lipid-based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol, 313, pp. 322-341.
27. Semple, SC Klimuk, SK et al. (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta, 1510:12, pp. 152-166.
28. Takeshita, F. Leifer, CA et al. (2001) Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol, 167:7, pp. 3555-3558.
29. Wilson, KD Raney, SG et al. (2007) Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol, 7:8, pp. 1064-1075.